–       Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful –       Graft and patient survival were 92% and 98%, respectively  –       Idefirix® was generally well tolerated with a safety profile consistent with previous clinical trial experience –       SERB acquired the European and MENA rights to […]

Multidisciplinary panel publishes 30 consensus statements to improve communication and shared decision-making in neuroblastoma care WEST CONSHOHOCKEN:  SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that “Bridging the Gap: Establishing Consensus for Improving Neuroblastoma Diagnosis and Care Experiences for Patients and Caregivers” has been published in Pediatric […]

BRUSSELS, 1 July 2026: SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from […]